EUVIMEDEUVIMED entdecken
Open Access

EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway

Naixiong Peng, Yuefeng Cai, Dong Chen, Ling Deng, Zejian Zhang, Wei Li

Oncology Research · 2025

DOI: 10.32604/or.2024.056039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Naixiong Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China. Hauptthemen laut MEDLINE: Early Growth Response Protein 1, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood.

Methods

The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to investigate EGR1's biological functions in ccRCC cells, involving proliferation, colony formation, invasion assays, and tumorigenesis in nude mice. In order to assess the protein expression of mitogen-activated protein kinase 15 (MAPK15), E-cadherin, matrix metalloproteinase-9/-2 (MMP-9 and MMP-2), Western blot technique was applied.

Results

The results revealed a decrease in EGR1 expression in ccRCC tissues. This decrease was strongly linked to TNM stage, lymphatic metastasis, tumor size, histological grade, and unfavorable prognosis in ccRCC patients. It has been demonstrated that overexpressing EGR1 inhibits the growth of xenograft tumors in vivo and inhibits cell colony formation, motility, and invasion in vitro. Furthermore, EGR1 can prevent the development and movement of ccRCC cells by controlling the expression of MMP-2, MMP-9, E-cadherin, and MAPK15.

Conclusions

The EGR1/MAPK15 axis may represent a promising target for drug development, with EGR1 serving as a possible target for ccRCC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Growth Response Protein 1Carcinoma, Renal CellKidney NeoplasmsHumansAnimalsCell ProliferationMiceFemaleMaleMiddle AgedCell Line, TumorMice, NudePrognosisGene Expression Regulation, NeoplasticCell MovementAged

Stichwörter der Autor:innen

Clear cell renal carcinoma (ccRCC)Early growth response factor 1 (EGR1)MigrationMitogen-activated protein kinase 15 (MAPK15)Proliferation

Substanzen

Early Growth Response Protein 1EGR1 protein, human

Autor:innen und Institutionen

  • Department of Urology, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.

Zitieren

APA

Peng, N., Cai, Y., Chen, D., Deng, L., Zhang, Z., & Li, W. (2025). EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway. Oncology Research. https://doi.org/10.32604/or.2024.056039

Vancouver

Peng N, Cai Y, Chen D, Deng L, Zhang Z, Li W. EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway. Oncology Research. 2025. doi:10.32604/or.2024.056039

BibTeX
@article{Peng2025,
  author = {Peng, Naixiong and Cai, Yuefeng and Chen, Dong and Deng, Ling and Zhang, Zejian and Li, Wei},
  title = {EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway},
  journal = {Oncology Research},
  year = {2025},
  doi = {10.32604/or.2024.056039}
}
Kostenlos starten →